Diagnosis and prevention of fungal infection in the immunocompromized patient

Blood Reviews

Volumn 12, Issue 4, 1998, Pages 241-254

  Richardson, M D ^a   Kokki, M H ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTACID AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CYCLODEXTRIN; FLUCONAZOLE; GAMMA INTERFERON; GLUCAN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; TUMOR NECROSIS FACTOR; VINCRISTINE;

ANTIGEN DETECTION; ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDIASIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COUGHING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMBINATION; DRUG DOSE; DRUG FORMULATION; DRUG INTERACTION; DRUG TISSUE LEVEL; DYSPNEA; EARLY DIAGNOSIS; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY DIAGNOSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 0032439484     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(98)90006-6     Document Type: Article

References (114)

1. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal fungal infections in neutropenic patients. Infectious Disease Clinics of North America 1996; 10: 365-400.
2. Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1997; 19: 801-808.
3. Ribud P. Fungal infections and the cancer patient. European J Cancer 1997; 33 (Suppl 4): S50-54.
4. Toren A, Or r, Ackerstein A, Nagler A. Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT). Bone Marrow Transplantation 1997; 20: 67-69.
5. Tumbarello M, Tacconelli E, Pagano L et al. Comparative analysis of prognostic indicators of aspergillosis in haematological malignancies and HIV infection. J Infect 1997; 34: 55-60.
6. Lyytikainen O, Ruutu T, Volin L et al. Late onset Pneumocystisi carinii pneumonia following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1996; 17: 1057-1059.
7. Richardson MD, Kokki MH. Antifungal therapy in bone marrow failure. Brit J Haematol 1998 (in press).
8. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. New England Journal of Medicine 1993; 328: 1323-1332.
9. Yuen K-Y, Woo PCY, Ip MSM et al. Stage-specific manifestations of mould infections in bone marrow transplant recipients: risk factors and clinical significance of positive concentrated smears. Clinical Infectious Diseases 1997; 25: 37-42.
10. Castagnola E, Bucci B, Montinaro E, Viscoli C. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol. Bone Marrow Transplant 1996; 18 (Suppl 2): 97-106.
11. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukaemia: the pathogenic role of the antileukemic regimen. Clinical Infectious Diseases 1995; 21: 361-369.
12. Hoover M, Morgan ER, Kletzel M. Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia. Medical and Pediatric Oncology 1997; 28: 268-273.
13. D'Antonio D, Iacone A, Schioppa FS, Bonifni T, Romano F. Effect of the current antimicrobial therapeutic strategy on fungal colonization in patients with hematologic malignancies. Current Microbiology 1996; 33: 118-122.
14. Granena A, Carreras E, Rozman C et al. Interstitial pneumonitis after bone marrow trransplantation: 15 years experience in a single institution. Bone Marrow Transplantation 1993; 11: 453-458.
15. Hoppe JE, Klingebiel T, Niethammer D. Orointestinal yeast colonization of paediatric bone marrow transplant recipients: surveillance by quantitative culture and serology. Mycoses 1994; 38: 51-57.
16. Kato YK, Hoshi Y, Akatsuka J, Suzuki M. The effects of antifungalchemoprophylaxis and empiric therapy on invasive fungal infection in neutropenic children with malignant neoplasms. Pediatric Hematol Oncol 1995; 12: 1-18.
17. Patterson JE, Zidouh A, Miniter P, Andriole VT, Patterson. Hospital epidemiologic surveillance for invasive aspergillosis: patient demographics and the utility of antigen detection. Infect Control Hosp Epidemiol 1997; 18: 104-108.
18. Wald A, Leisenring W, van Burik J-A, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. Journal of Infectious Diseases 1997; 175: 1459-1466.
19. Martino P, Girmenia C, Micozzi A, De Bernardis F, Boccanera M, Cassone A. Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. European Journal of Microbiology and Infectious Diseases 1994; 13: 797-804.
20. Anttila V-J, Elonen E, Nordling S, Sivonen A, Ruutu T, Ruutu P. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clinical Infectious Diseases 1997a; 24: 375-380.
21. Denning DW, Evans EGV, Kibbler CC et al. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. European Journal of Clinical Microbiology and Infectious Diseases 1997; 16: 424-436.
22. LaRocco MT, Burgert SI Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation. Clin Microbiol Rev 1997; 10: 277-297.
23. Graham NJ, Muller NL, Miller RR, Shepherd JD. Intrathoracic complications following allogeneic bone marrow transplantation: CT findings. Radiology 1991; 181: 153-156.
24. Caillot D, Casasnovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. Journal of Clinical Oncology 1997; 15: 139-147.
25. Verweij PE, Donnelly JP, De Pauw BE, Meis JFGM. Prospects for the early diagnosis of invasive aspergillosis in the immunocompromised patient. Rev Med Microbiol 1996; 7: 105-113.
26. Hearn V, Pinel C, Blachier S, Ambroise-Thomas P, Grillot R. Antibody detection in invasive aspergillosis by analytical isoelectrofocusing and immunoblotting methods. J Clin Microbiol 1995; 33: 982-986.
27. Hopfer RL, Waiden P, Setterquist S, Highsmith WE. Detection and differentiation of fungi in clinical specimens using polymerase chain reaction (PCR) amplification and restriction enzyme analysis. J Med Vet Mycol 1993; 31: 65-75.
28. Sandhu GS, Kline BC, Stockman L, Roberts GD. Molecular probes for diagnosis of fungal infections. J Clin Microbiol 1995; 33: 2913-2919.
29. Obayashi T, Toshida M, Mori T et al. Plasma (1->3) - D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17-20.
30. Severens JL, Donnelly JP, Meis JFGM, De Vries Robbe PF, De Pauw BE, Verweij PE. Two strategies for managing invasive aspergillosis: a decision analysis. Clinical Infectious Diseases 1997; 25: 1148-1154.
31. Walsh TJ, Chanock SJ. Laboratory diagnosis of invasive candidiasis: a rationale for complementary use of culture-and nonculture-based detection systems. Int J Infect Dis 1997; 1(Suppl 1): S11-S19.
32. Anttila V-J, Ruutu P, Bondestam S et al. Hepatosplenic yeast infection in patients with acute leukemia: a diagnostic problem. Clinical Infectious Diseases 1994; 18: 979-981.
33. Anttila V-J, Farkkila M, Jansson SE et al. Diagnostic laparoscopy in patients with acute leukemia and suspected hepatatic candidiasis. European Journal of Clinical M icrobiology and Infectious Diseases 1997b; 16: 637-643.
34. Chanock SJ, Walsh TJ. Molecular diagnosis of Candida infection in the compromised host: current status and future prospects. International Journal of Infectious Diseases 1997; 1 (Suppl 1): S20-S24.
35. Lehtonen L, Anttila V-J, Ruutu T et al. Diagnosis of disseminated candidiasis by measurement of urine D-arabinitol/L-arabinitol ratio. J Clin Micro 1996; 34: 2175-2179.
36. Beyer J, Schwartz S et al. Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients. Antimicrob Agents Chemother 1994; 38: 911-917.
37. Sheretz RJ, Belani A et al. Impact of air filtration on nosocomial aspergillus infections Am J Med 1987; 8: 709-718.
38. Rhame FS. Prevention of nosocomial aspergillosis. J Hosp Infect 1991; 18, Suppl A: 466-472.
39. Hay RJ. The prevention of invasive aspergillosis - a realistic goal? J Antimicrob Chemother 1993; 32: 515-517.
40. Dekker AW, Verdonck LF, Rozenberg-Arska M. Infection prevention in autologous bone marrow transplantation and the role of protective isolation. Bone Marrow Transplantation 1994; 14: 89-93.
41. Loo VG, Bertrand C, Dixon C et al. Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. Infect Control Hosp Epidemiol 1996; 17: 360-364.
42. Iwen PC, Davis JC et al. Airborne fungal spore monitoring in a protective environment during hospital contruction, and correlation with an outbreak of invasive aspergillosis. Infect Control Hosp Epidemiol 1994; 15: 303-306.
43. Anderson K, Morris G, Richardson MD et al. Aspergillosis in Immunocompromised paedriatric patients: associations with building hygience. design and indoor air, Thorax 1996; 51: 256-261.
44. Opal SM. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 1986; 153: 634-637.
45. Goodley JM, Clayton YM, Hay RJ. Environmental sampling for aspergilli during building construction on a hospital site. J Hosp Infect 1994; 26: 27-35.
46. Milliken ST, Powles RL. Antifungal prophylaxis in bone marrow transplantation. Rev Infect Dis 1990; 12 (Suppl 3): S374-S379.
47. Cap J, Mojzesova A, Kayerova E, Bubanska E et al. Fluconazole in children: first experience with prophylaxis in chemotherapy-induced neutropenia in pediatric patients with cancer. Chemotherapy 1993; 39: 438-442.
48. Bjorkholm M. Chemoprophylaxis of fungal infections in neutropenic patients. Annals of Oncology 1994; 5: 571-574.
49. Cowie F, Meller ST, Gushing P, Pinkerton R. Chemoprophylaxis for pulmonary aspergillosis during intensive chemotherapy. Arch Dis Child 1994; 70: 136-138.
50. Meunier F, Paesmans M, Autier P. Value of antifungal prophylaxis with antifungal drugs against oropharyngeal candidiasis in cancer patients. Oral Oncol, Eur J Cancer 1994; 30B: 196-199.
51. Schaffner A. Prophylaxis and treatment of fungal infections in cancer patients. Bailliere's Clin Infect Dis 1994; 1: 499-522.
52. Annaloro C, Oriani A, Tagliaferri E et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologia 1995; 80: 512-517.
53. Lam HH, Althaus BL. Antifungal prophylaxis in bone marrow transplantation. Ann Pharmacother 1995; 29: 921-924.
54. Klastersky J. Prevention and therapy of fungal infections in cancer patients: a review of recently published information. Support Care Cancer 1995; 3: 393-401.
55. Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematological malignancies: a reappraisal. Blood 1995; 86: 2063-2072.
56. Boogaerts MA. Antifungal prophylaxis in neutropenic patients. International Journal of Antimicrobial Agents 1996; 6: 149-154.
57. Chanock SJ, Walsh TJ. Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients. Bone Marrow Transplantation 1996; 18 (Suppl 3): S15-S20.
58. Epstein JB, Ransier A, Lunn R et al. Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants. Oral Surg Oral Medicine Oral Pathology Oral Radiology Endod 1996; 81: 291-296.
59. Guiot HFL, Fibbe WE. Prevention of oral candidiasis and systemic fungal infection in patients with hematologic malignancies. J Mycol Med 1996; 6: 26-30.
60. Philpott-Howard JN. Prevention of fungal infections in hematology patients. Infect Control Hosp Epidemiol 1996; 17: 545-551.
61. Bowden RA. Prevention of candidal infection in immunocompromised patients: what for whom? International Journal of Infectious Diseases 1997; 1 (Suppl 1): S47-S51.
62. De Pauw BE. Practical modalities for prevention of fungal infections in cancer patients. European Journal of Clinical Microbiology and Infectious Diseases 1997; 16: 32-41.
63. Dictar M. Prevention of candidiasis in bone marrow transplantation patients: a comparison of different approaches. International Journal of Infectious Diseases 1997; 1 (Suppl 1): S56-S59.
64. Edwards JE, Bodey GP. Bowden RA et al. International conference for the development of a consensus on the management and of severe candidal infections. Clinical Infectious Diseases 1997; 25: 43-59.
65. Gøtzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. British Medical Journal 1997; 314: 1238-1244.
66. Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Revs 1997; 10 (3): 477-504.
67. Menichetti F. Prevention of candidiasis in the immunocompromised host: what are the best strategies?. Internat J Infect Dis 1997; 1 (Suppl 1): S52-S55.
68. Palmblad J. Oral azole prohylaxis for fungal infections during induction therapy for acute leukemia: more bacteremias and neutropenias? Int J Infect Dis 1997; 1 (Suppl 1): S60-S63.
69. Serody JS, Shea TC. Prevention of infections in bone marrow transplant recipients. Infect Dis Clin N Amer 1997; 11: 459-477.
70. Jorgensen CJ, Dreyfus F, Vaixeler J et al. Failure of amphotericin B spray to prevent aspergillosis in granulocytopenic patients. Nouvelle Revue Francaise d'Hematologie 1989; 31: 327-328.
71. Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplantation 1990; 5: 403-406.
72. Jeffrey GM, Beard MJ, Ikram RB et al. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991; 90: 685-691.
73. Meyers SE, Devine SM, Topper RL et al. A pilot study of prophylactic aerolsolized amphotericin B in patients ar risk for prolonged neutropenia. Leukaemia and Lymphoma 1992; 8: 229-233.
74. Beyer J, Barzen G, Schwartz S et al. Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1993; 37: 1367-1369.
75. Beyer J, Schwartz S, Barzen G et al. Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection 1994; 22: 143-148.
76. Hertenstein B, Kern WV, Schmeister T et al. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 1994; 68: 21-26.
77. Riley DK, Pavia AT, Beatty PG et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97: 509-514.
78. Behre GF, Schwartz S, Lenz K et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Annals of Hematology 1995; 71: 287-291.
79. Trigg ME. Morgan D, Burns TL et al. Successful program to prevent aspergillus infections in children undergoing marrow transplantation: use of nasal amphotericin. Bone Marrow Transplant 1997; 19: 43-47.
80. Erjavec Z, Woolthuis GMH, de Vries-Hospers HG et al. Tolerance and efficacy of amphotericn B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. European Journal of Clinical Microbiology and Infectious Diseases 1997; 16: 364-368.
81. Dubois J, Bartter T, Gryn J, Pratter MR. The physiologic effects of inhaled amphotericin B. Chest 1995; 108: 750-753.
82. Sorensen KN, Allen SD, Nejdl MJ, Proffitt RT. Aerosolization of liposomal (AmBisome®) and nonliposomal (Fungizone®) amphotericin B as a treatment for pulmonary fungal infections. Journal of Controlled Release 1994; 28: 346-347.
83. Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proffit RT. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy, 1994; 34: 1001-1013.
84. Todeschini G, Murari C, Bonesi R et al. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1993; 12: 614-618.
85. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991; 91: 484-492.
86. Perfect JR, Klotman ME, Gilbert CC et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165: 891-897.
87. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplantation 1993; 12: 577-582.
88. Glasmacher A, Molotor E, Mezger J, Marklein G. Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbiological and clinical aspects. Mycoses 1996; 39: 249-258.
89. Bohme A, Just-Nubling G, Bergmann L, Shah PM, Stille W, Hoelzer D. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. Journal of Antimicrobial Chemotherapy 1996; 38: 953-961.
90. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Baule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32: (Suppl 1) 103-108.
91. Persat F, Marzullo C, Guyotat D, Rochet M-J, Piens M-A. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992; 28A: 838-841.
92. Poirier JM, Berlioz F, Isnard F, Cheymol G. Marked intra-and inter-patient variability of itraconazole steady state plasma concentrations. Therapie 1996; 51: 163-167.
93. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Annals of Hematology 1995; 71: 311-312.
94. Prentice AG, Warnock DW, Johnson SAN, Phillips MJ, Oliver DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrobial Chemother 1994; 34: 247-252.
95. Prentice AG, Warnock DW, Morgenstern GR, Prentice HG, Ropner JE, Schey SA. Serum concentrations of itraconazole in neutropenic patients receiving Sporonox liquid. Abstract of the 39th Annual Meeting of the American Society of Hematology, San Diego, December 1997.
96. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW Itraconazole (IT) oral solution vs fluconazole (F) suspension for antigungal prophylaxis in neutropenic patients. Abstract of the 36th ICAAC, New Orleans, September 1996.
97. Alangaden G, Chandrasekar PH, Bailey E, Khaliq Y and the Bone Marrow Transplantation Team. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. Bone Marrow Transplantation, 1994; 14: 919-924.
98. Egger T, Gratwohl A, Tichelli A et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. Support Care Cancer 1995; 3: 139-146.
99. Ehninger G, Schuler HK, Sarnow E. Fluconazole in the prophylaxis of fungal infection after bone marrow transplantation. Mycoses 1996; 39: 259-263.
100. Ellis ME, Clink H, Ernst P et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994; 13:3-11.
101. Preston SL, Briceland LL. Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia. Am J Health-Syst Pharm 1995; 52: 164-173.
102. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
103. Tortorano AM, Viviani MA, Pagano A et al. Candida colonization on orthoptic liver transplantation: fluconazole versus oral amphotericin B. J Mycol Med 1995; 5: 21-24.
104. Van Delden C, Lew DP, Chapuis B, Rohner P, Hirschel B. Antifungal prophylaxis in severely neutropenic patients: how much fluconazole is necessary? J Clin Microbiol Infect 1995; 1: 24-30.
105. Yamac K, Senol E, Haznedar R. Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad Med J 1995; 71: 284-286.
106. Chandrasekar PH, Gatny CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Chemotherapy 1994; 40: 136-143.
107. Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118: 495-503.
108. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
109. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia: fluconazole versus intravenous amphotericin B. Cancer 1994; 73: 2099-2106.
110. Wakerly L, Craig A-M, Malek M. et al. Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysis. J Hosp Infect 1996; 33: 35-48.
111. Stewart A, Powles, Hewetson M, Antrum J, Richardson C, Mehta J. Costs of antifungal prophylaxis after bone marrow transplantation. Pharmacoeconomics 1995; 8: 350-361.
112. Philpott-Howard JN, Wade JJ, Mufti GJ et al. Randomised comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993; 31: 973-984.
113. Ninane J. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Eur J Clin Microbiol Infect Dis 1994; 13: 330-337.
114. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallego I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. Journal of Infectious Diseases 1997; 176: 227-232.